Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

Oncogenic tyrosine kinases have proven to be promising targets for the development of highly effective anticancer drugs. However HER family tyrosine kinase inhibitors (TKIs) show only limited activity against HER2-driven cancers despite effective inhibition of EGFR and HER2 in vivo 1–8. The reasons...

Descripción completa

Detalles Bibliográficos
Autores principales: Sergina, Natalia V., Rausch, Megan, Wang, Donghui, Blair, Jimmy, Hann, Byron, Shokat, Kevan M., Moasser, Mark M.
Formato: Texto
Lenguaje:English
Publicado: 2007
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025857/
https://www.ncbi.nlm.nih.gov/pubmed/17206155
http://dx.doi.org/10.1038/nature05474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025857/
https://www.ncbi.nlm.nih.gov/pubmed/17206155
http://dx.doi.org/10.1038/nature05474

Ejemplares similares